It is the first orally administered therapy for the treatment of two types of ANCA-associated vasculitis approved in Japan
Surufatinib is the third potential new medicine discovered by the company to enter into clinical development in Japan
Takeda is establishing the capability to manufacture TAK-019 (known outside Japan as NVX-CoV2373) at its facilities in Japan and aims to begin distribution in the early calendar year 2022
Over 13 million people in Japan suffer from chronic kidney disease and this will transform treatment options
In the SHORE phase 3 study, amlitelimab, used in combination with topical therapies, met all primary and key secondary endpoints at Week 24
The company has posted net profit of Rs. 4,064.9 crore for the 9 months period ended December 31, 2025
The registrations grant Neurizon exclusive rights to use and defend its brand across its core operating regions
LOTTE Biologics will provide advanced manufacturing services for monoclonal antibody intermediates and their conjugates
The clearance marks a major step in Diabeloop’s ambition to become a central partner for insulin pump manufacturers and expand access to automated insulin delivery in the US market
Nxera will take full responsibility for regulatory approvals, clinical development where required, manufacturing and commercialization in the licensed territories
Subscribe To Our Newsletter & Stay Updated
